AL-15469A + AL-6515

AL-15469A + AL-6515 is a fixed-dose combination ophthalmic suspension developed for the treatment of acute contagious conjunctivitis and potentially other ocular surface infections. AL-15469A is the code name for moxifloxacin hydrochloride, a fourth-generation fluoroquinolone antibiotic that acts as a DNA gyrase inhibitor and type II topoisomerase inhibitor, thereby inhibiting bacterial DNA replication[9]. AL-6515 is less well characterized in public sources but appears to be an additional active ingredient formulated with moxifloxacin in this combination product. The combination aims to provide broad-spectrum antibacterial activity for topical ocular use[1][9]. The product has been evaluated in clinical studies as an ophthalmic suspension at concentrations of 0.5% (AL-15469A) and 0.3% (AL-6515)[1].

Other names

moxifloxacin 0.5% / nepafenac 0.3% ophthalmic suspension